FDA awards BioCryst’s Orladeyo NDA for paediatric HAE
The US Food and Drug Administration (FDA) has accepted BioCryst Pharmaceuticals’ new drug application (NDA) for Orladeyo.
The US Food and Drug Administration (FDA) has accepted BioCryst Pharmaceuticals’ new drug application (NDA) for Orladeyo.
What's Your Reaction?
